This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Hold On to Baxter (BAX) Stock Now
by Zacks Equity Research
Baxter's (BAX) cyclophosphamide performance continues to remain dismal. Nevertheless, the company witnesses positive tidings of other products on the regulatory front.
Why Integer (ITGR) is a Top Pick for Momentum Investors
by Zacks Equity Research
Does Integer (ITGR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Amedisys Ties Up With Medalogix to Boost Home Health Unit
by Zacks Equity Research
Amedisys (AMED) pursues deals to boost Home Health business.
Cooper Companies (COO) Earnings Miss & Revenues Beat in Q3
by Zacks Equity Research
Cooper (COO) gains from solid CSI revenues in Q3; international revenues surge.
Here's Why You Should Invest in Veeva (VEEV) Stock Right Now
by Zacks Equity Research
Strong fundamentals and a solid Q2 aid Veeva (VEEV).
Glaukos (GKOS) Jumps: Stock Rises 7.2%
by Zacks Equity Research
Glaukos (GKOS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Illumina MiSeq Dx Okayed in China, NGS Platform Gets a Boost
by Zacks Equity Research
Illumina's (ILMN) receipt of CNDA approval for MiSeq Dx Sequencing System is expected to expand customer base and boost the top line.
Here's Why You Should Invest in Phibro (PAHC) Right Now
by Zacks Equity Research
Phibro (PAHC) sees improvement across all segments. The Animal Health business has been a key contributor.
Patterson Companies (PDCO) Misses Q1 Earnings Estimates
by Zacks Equity Research
Patterson Companies' (PDCO) adjusted earnings declines considerably on a year-over-year basis in Q1. Lackluster performance by the dental unit is a concern.
Here's Why You Should Buy Inogen (INGN) Stock Right Now
by Zacks Equity Research
Inogen (INGN) gains from strong Q2 results and bright global prospects.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Genomic Health (GHDX) gains ground on growing adoption of prostate cancer test and solid international scenario.
Ecolab's Nalco Pairs With XOS to Boost Global Energy Unit
by Zacks Equity Research
Ecolab's (ECL) Nalco Champion's 3D CRUDEFLEX will integrate XOS' Clora Online; market prospects bright.
Here's Why You Should Hold On to Stryker (SYK) Stock Now
by Zacks Equity Research
Challenging global economic conditions and supply-side issues are major deterrents to Stryker's (SYK) top line in the near term. The company's significant exposure to robotics is a positive.
New Buyouts Aid Boston Scientific Amid Dull Pacemaker Sales
by Zacks Equity Research
Boston Scientific (BSX) continues to adopt organic as well as inorganic routes for success. However, sluggish global pacemaker sales continue to disappoint.
Phibro Animal (PAHC) Q4 Earnings Beat, Sales Improve Y/Y
by Zacks Equity Research
Phibro (PAHC) witnesses year-over-year improvement across all segments in Q4.
Wright Medical Buys Cartiva to Boost Lower Extremities Unit
by Zacks Equity Research
Wright Medical's (WMGI) addition of Synthetic Cartilage Implant is likely to drive revenues in 2019; raised guidance for 2018 encourages.
Here's Why You Should Hold On to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) is expected to benefit from lucrative prospects in the diabetes market. However, the company's margins were under pressure in the last reported quarter.
STERIS (STE) Strategic Growth Strong, Competition a Woe
by Zacks Equity Research
STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.
Bruker to Expand Molecular Diagnostics Arm With Hain Buyout
by Zacks Equity Research
Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.
Omnicell Patient Engagement Unit to Aid Medication Adherence
by Zacks Equity Research
Omnicell's (OMCL) revamped Patient Engagement platform likely to aid core Medication Adherence Unit; market looks promising.
Here's Why You Should Invest in Integer (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) gains on strong quarterly performance. The company is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.
Cerner, Duke Clinical Research Launch Risk Calculator App
by Zacks Equity Research
Cerner (CERN) launches new Risk Calculator app that will check cardiac risk. The company's relentless efforts to digitize its EHR systems is commendable.
Medtronic (MDT) Grows on CRHF Arm, Margin Pressure Ails
by Zacks Equity Research
Solid demand for Medtronic's (MDT) quadripolar cardiac resynchronization therapy-pacemakers (CRT-P) along with growth in Mechanical Circulatory Support drives Heart Failure division revenues.
Hill-Rom (HRC) Touches 52-Week High: What's Driving It?
by Zacks Equity Research
Hill-Rom (HRC) rides high on impressive Q3 results along with increased focus on product innovation through research and development.
Veeva Systems (VEEV) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems (VEEV) gains from its flagship Vault platform. Also, expanding margins are an added positive for the company.